24/7 Wall Street
25 Feb 2026, 18:33 UTC · 28w ago
Verdict
Headline leans bullish. We score IOVA +1.00 across five claims.
Score confirms the headline.
IOVA score
+1.00
More positive than 99% of ticker scores this week
Price reaction
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen
What the story claims
5 claims · scored −1 bearish … +1 bullish
Iovance Biotherapeutics received FDA Fast Track designation for NSCLC, targeting a market seven times larger than melanoma.
More positive than 98% of claims this week
The company internalized manufacturing at its Philadelphia facility, supporting 5,000 patients annually with a 32-day turnaround.
So whatInternalized production creates a competitive moat and structural cost advantages that improve margins.
Continue reading
5 related stories
Top 1 mover · tap to explore
More positive than 91% of claims this week
Q4 revenue reached $86.71 million (up 17.7% YoY) with gross margins expanding to 50% from 38.2%.
More positive than 85% of claims this week
The company expects 'remarkable revenue growth in 2026' with formal guidance forthcoming.
More positive than 77% of claims this week
NSCLC trial enrollment completion and the soft tissue sarcoma Phase 2 launch are scheduled for Q2 2026.
More positive than 66% of claims this week
Which stocks this story touches
More positive than 99% of ticker scores this week
Strong Q4 revenue growth, expanding gross margins, and positive analyst sentiment.
More positive than 88% of ticker scores this week
Shares surged 35.4% alongside a shift in positive retail investor sentiment.
More negative than 82% of ticker scores this week
Shares fell significantly and the stock has pulled back sharply.
More positive than 77% of ticker scores this week
Posted Q1 2026 results that beat revenue expectations.
More positive than 77% of ticker scores this week
Posted Q1 2026 results that beat revenue expectations.
More negative than 75% of ticker scores this week
Mentioned as having pulled back sharply.
More negative than 75% of ticker scores this week
Mentioned as having pulled back sharply.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
7h ago
Price reaction
Expected +1.00Actual +127.5%
Price agrees with the score
138 sessions since publication. $8.60 vs $3.78 close before publication (Feb 24). Not market-adjusted.
IOVA chart →
